In March 2023, this initiative was launched by the Centre of Research in Epidemiology and StatisticS (Université de Paris) and Cochrane France, with the collaboration of the World Health Organization (WHO), Université Paris Cité, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan and the Epistemonikos Foundation, with the conviction that decisions on health interventions in COVID-19 should be informed by a living evidence ecosystem developed by an international collaborative effort.
Thus, COVID-NMA's mission is to inform scientific research planning by producing an up-to-date mapping of evidence from experimental trials, as well as to inform public health decisions by producing a synthesis of evidence on the efficacy and safety of COVID-19 prevention or treatment interventions that is high quality, reliable, relevant, accessible, and up-to-date. In addition, part of its mission is to enhance the value of research by producing living monitoring of the planning, conduct, and reporting of experimental trials, and implementing interventions to transform research practices.
To achieve its goal, COVID-NMA produced a live mapping of COVID-19 trials, a live monitoring of COVID-19 trial transparency, and a live systematic review of COVID-19 trial results. For the latter resource, the consortium used L.OVE and the Cochrane COVID-19 Study Register Platform to identify trials with results on a daily frequency. The methodology is published.
In March 2023, this initiative was launched by the Centre of Research in Epidemiology and StatisticS (Université de Paris) and Cochrane France, with the collaboration of the World Health Organization (WHO), Université Paris Cité, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan and the Epistemonikos Foundation, with the conviction that decisions on health interventions in COVID-19 should be informed by a living evidence ecosystem developed by an international collaborative effort.
Thus, COVID-NMA's mission is to inform scientific research planning by producing an up-to-date mapping of evidence from experimental trials, as well as to inform public health decisions by producing a synthesis of evidence on the efficacy and safety of COVID-19 prevention or treatment interventions that is high quality, reliable, relevant, accessible, and up-to-date. In addition, part of its mission is to enhance the value of research by producing living monitoring of the planning, conduct, and reporting of experimental trials, and implementing interventions to transform research practices.
To achieve its goal, COVID-NMA produced a live mapping of COVID-19 trials, a live monitoring of COVID-19 trial transparency, and a live systematic review of COVID-19 trial results. For the latter resource, the consortium used L.OVE and the Cochrane COVID-19 Study Register Platform to identify trials with results on a daily frequency. The methodology is published.